Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial.
henagliflozin 對於有 HFpEF 的透析病人左心室質量指數的影響 (HELD-HF):一項多中心、隨機、雙盲、安慰劑對照試驗的研究計劃。
BMJ Open 2024-08-27
Efficacy of dapagliflozin in the treatment of HFrEF with obstructive sleep apnea syndrome (DAHOS study): study protocol for a multicentric, prospective, randomized controlled clinical trial.
dapagliflozin 在治療伴有阻塞性睡眠呼吸暫停症的 HFrEF 的療效(DAHOS 研究):多中心、前瞻性、隨機對照臨床試驗的研究方案。
Trials 2023-05-13
Effects of empagliflozin on cardiac structure, function and biomarkers in patients with heart failure with preserved ejection fraction: study protocol for a randomised, placebo-controlled prospective trial.
Empagliflozin對心臟收縮功能保留型心衰患者心臟結構、功能和生物標記的影響:隨機、安慰劑對照前瞻性試驗的研究方案。
BMJ Open 2023-09-04
SGLT2 inhibitors among patients with heart failure with preserved ejection fraction: A meta-analysis of randomised controlled trials.
心臟衰竭伴隨保留射血分數患者中SGLT2抑制劑的使用:隨機對照試驗的荟萃分析。
Medicine (Baltimore) 2023-10-05
Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED).
腹膜透析患者中鈉葡萄糖共同轉運蛋白2抑製劑對超過濾的影響:EMPOWERED試驗的隨機、雙盲、安慰劑對照、交叉研究方案。
Clin Exp Nephrol 2024-02-25
Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction.
empagliflozin對2型糖尿病或糖尿病前期心臟衰竭患者左心室容積的影響。
Acta Cardiol 2024-03-21
Empagliflozin in type 2 diabetes with and without CKD and non-diabetic CKD: Protocol for 3 randomized, double-blind, placebo controlled cross-over trials.
Empagliflozin在2型糖尿病合併腎病變和非糖尿病性腎病變中的使用:3項隨機、雙盲、安慰劑對照交叉試驗的方案。
JMIR Res Protoc 2024-04-29
Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial).
探討 Tofogliflozin 對心臟衰竭合併保留射血分數及第2型糖尿病患者左心室舒張功能障礙之療效的前瞻性、多中心、雙臂臨床試驗(TOP-HFPEF 試驗)的理念與設計。
Cardiovasc Drugs Ther 2024-05-10
Effect of Sodium-Glucose Co-Transporter-2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction.
鈉-葡萄糖共轉運蛋白-2抑制劑對於射血分數降低的心衰竭患者及射血分數保留的心衰竭患者的估計血漿容量影響。
Clin Cardiol 2024-07-20